184 related articles for article (PubMed ID: 28574300)
1. Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.
Liu FR; Jin H; Wang Y; Chen C; Li M; Mao SJ; Wang Q; Li H
Drug Deliv; 2017 Nov; 24(1):882-890. PubMed ID: 28574300
[TBL] [Abstract][Full Text] [Related]
2. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
[TBL] [Abstract][Full Text] [Related]
3. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells.
Wang Y; Liu F; Wang Q; Xiang H; Jin H; Li H; Mao S
Int J Pharm; 2017 Aug; 529(1-2):531-542. PubMed ID: 28583331
[TBL] [Abstract][Full Text] [Related]
4. Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment.
Guo D; Xu P; Chen D; Wang L; Zhu Y; Zuo Y; Chen B
Int J Nanomedicine; 2020; 15():521-536. PubMed ID: 32021192
[TBL] [Abstract][Full Text] [Related]
5. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
6. [Preparation of CD123 mono-antibody modified tanshinone ⅡA loaded immunoliposome and its in vitro evaluation].
Wang Y; Liu FR; Xiang HL; Qing H; Chen C; Mao SJ; Li H
Zhongguo Zhong Yao Za Zhi; 2017 Jun; 42(11):2085-2091. PubMed ID: 28822152
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
8. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
9. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
10. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
[TBL] [Abstract][Full Text] [Related]
12. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
13. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
Li B; Zhao W; Zhang X; Wang J; Luo X; Baker SD; Jordan CT; Dong Y
Bioorg Med Chem; 2016 Nov; 24(22):5855-5860. PubMed ID: 27687970
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
15. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia.
Xu S; Zhang M; Fang X; Meng J; Xing H; Yan D; Liu J; Yang Y; Wen T; Zhang W; Wang J; Wang C; Xu H
J Hematol Oncol; 2021 Nov; 14(1):193. PubMed ID: 34774070
[TBL] [Abstract][Full Text] [Related]
16. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
[TBL] [Abstract][Full Text] [Related]
17. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
[TBL] [Abstract][Full Text] [Related]
18. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
Zhou T; Chen ML; Zhang CY; Liu XY; Wang ZZ; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):225-232. PubMed ID: 38716593
[No Abstract] [Full Text] [Related]
19. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
20. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
